{"prompt": "['63', 'MC1488 WEE1', 'MCCC', 'If the true CR/CRi rate is', '0.05', '0.10', '0.15', '0.20', '0.25', 'Then the probability of', \"declaring that a given arm's\", '0.08', '0.32', '0.60', '0.79', '0.91', 'treatment regimen warrants', 'further studies is', 'Probabilities for the combination arm being selected as the overall winner are', 'provided in the following table.', 'CR/CRi rate', 'CR/CRi rate', 'Probability combo selected over', '(AZD1775 alone)', '(AZD1775 + AraC)', 'single-agent arm', '0.05', '0.05', '0.07', '0.25', '0.25', '0.30', '0.20', '0.25', '0.44', '0.15', '0.25', '0.61', '0.10', '0.25', '0.77', '0.05', '0.25', '0.88', '16.3 Sample Size, Accrual Rate, and Study Duration', 'This design is expected to accrue 18 patients to the safety portion with the possibility of', 'enrolling up to 54. Six patients in each of the safety arms will be treated at the MTD and', 'thus will be eligible for primary endpoint analysis. An additional 15 patients in Arm A', 'and 14 patients in both arm B and C will be enrolled per treatment arm in the expansion', 'portion with the addition of another 2 per arm to account for ineligibility, cancellation,', 'major treatment violation, or other reasons. Thus the final accrual may be as large as 102', 'or as low as 67 (Arm A: 23; Arm B: 22; Arm C: :22).', 'The anticipated accrual rate is 4-6 evaluable patients per month. Therefore, the accrual', 'period is expected to be approximately 1.5-2 years. The primary endpoint will be', 'evaluated approximately 2.5 years after the trial opens, or after the last patient accrued', 'has been observed for at least 4 months. The total study duration is expected to be', 'approximately 2.5 years.', '16.4', 'Secondary Endpoints', '16.41 Safety and tolerability data will be compiled. The maximum grade for each type', 'of adverse event will be recorded for each patient, and frequency tables will be', 'reviewed to determine patterns (by arm, disease and overall). Additionally, the', 'relationship of the adverse event(s) to the study treatment will be taken into', 'consideration. The rate of grade 3 or higher non-hematologic adverse events, and', 'the rate of grade 4 or higher adverse event (hematologic and non-hematologic)', 'will be computed each with a 95% exact binomial confidence interval.', '16.42', 'Summary statistics for clinical benefit (mean and standard deviations for', 'continuous variables and frequencies and percentages for discrete variables) will', 'be compiled for hematologic improvements and transfusion requirements.']['64', 'MC1488 WEE1', 'MCCC', '16.43 Duration of response is defined for all evaluable patients who have achieved a', \"response as the date at which the patient's earliest best objective status is first\", 'noted to be a CR/CRi response to the earliest date progression is documented. If', 'a patient dies subsequent to the response without a documentation of disease', 'progression, the patient will be censored at the last date disease was assessed. In', 'the case of a patient failing to return for evaluations before a documentation of', 'disease progression, the patient will be censored for progression on the date of', 'last evaluation. The distribution of duration of response will be estimated using', 'the method of Kaplan-Meier (1958).', '16.44 Time to response/progression is defined as the time from registration to the', 'earliest date of documentation of response/disease progression. If a patient dies', 'without a documentation of disease progression the patient will censored at the', 'last date disease was assessed. In the case of a patient starting treatment and then', 'never returning for any evaluations, the patient will be censored for progression 1', 'day post-registration. The distribution of time to progression will be estimated', 'using the method of Kaplan-Meier (1958).', '16.45', 'Survival time is defined as the time from registration to death due to any cause.', 'The distribution of survival time will be estimated using the method of Kaplan-', 'Meier (1958).', '16.46', 'Time to AML or death is defined for all evaluable patients with MDS as the time', 'from registration to leukemic transformation or death due to any cause. The', 'distribution of time to AML or death will be estimated using the method of', 'Kaplan-Meier (1958).', '16.5', 'Exploratory Analysis', 'An exploratory analysis will be conducted, if there is indication, to determine any', 'differences in study endpoints for subgroups of patients within each treatment arm as', 'defined by the grouping factors (section 5.0), descriptive factors (section 12.0), dose level', 'or any other patient demographics.', '16.6', 'Correlative Research', '16.61', 'Statistical analysis of pharmacokinetics and biomarkers will be primarily', 'descriptive. Continuous biomarker levels will be explored in a graphical manner', 'including mean plots and plots of change and percent change from baseline and', 'other summary measures. Any potential relationships between the baseline level', 'or change in the level of each biomarker and clinical outcome such as overall', 'response, 6-month progression and survival, and adverse event incidence will be', 'further analyzed using Wilcoxon rank sum tests or logistic regression methods, as', 'appropriate. Association between a dichotomized biomarker and overall', 'response will be assessed using a chi-squared test. Comparisons with 1-sided p-', 'values 0.10 are considered significant. As this correlative component is', 'exploratory in nature, we have not adjusted for multiple comparisons.', '16.62', 'Patient-reported outcomes will be assessed at baseline and at the end of each', 'cycle of treatment. MPN-SAF TSS was created to address the constellation of']\n\n###\n\n", "completion": "END"}